

BIOFIL CHEMICALS & PHARMACEUTICALS LTD.

Regd. Office : 11/12, Sector-E, Sanwer Road, Industrial Area, Indore - 452 015. Fax : 0731-2723017
Tel. : 0731-2723016, 4066216 E-mail : biofilchemicals@yahoo.com / bcplcompliance@gmail.com
Factory : Plot No. 8, Sector - IV, Kheda Industrial Area, Pithampur Distt. Dhar (M.P.)

Admn. Office : B-12/B, Industrial Estate, Pologround, Indore - 452 015 (M.P.)
Tel. : 0731-2426700, 2426718, 2524003, Fax : 0731-2426726 • CIN : L24233MP1985PLC002709

Date: 11th November 2020

To, The Company Secretary, Corporate Compliance Department The National Stock Exchange of India Limited Bandra Kurla Complex, Mumbai	To, The Company Secretary Corporate Compliance Department BSE Limited Dalal Street, P.J. Tower, Mumbai
--	--

Subject: - Outcome of the Board Meeting held on Wednesday, 11th November 2020 pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosures Requirements) Regulations 2015.

Ref: BIOFIL CHEMICALS & PHARMACEUTICALS LIMITED (BSE Scrip Code: 524396; NSE Symbol: BIOFILCHEM, ISIN: INE829A01014)

Dear Sir/Mam

With reference to the above-mentioned subject, we would like to inform that Board of the Directors of the Company in their Meeting (Serial No. 03/2020-2021) held on today i.e. Wednesday 11th November 2020, has inter alia, transacted following matters along with other routine businesses:-

1. Un-Audited Financial Result of the Company for the Quarter and Half year ended 30th September, 2020 along with Statement of Assets and Liabilities, Cash Flow Statement, Segment Reporting and Limited Review Report thereon.
2. Approval of revised Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information (UPSI).

This is further to inform you that the Board meeting was commenced at 6.00 p.m. and concluded at 6.45 p.m.

This is for your information and record

Thanking You,

Yours faithfully

For Biofil Chemicals and Pharmaceuticals Limited

Ramesh Shah
Managing Director



Biofil Chemicals and Pharmaceuticals Limited

Registered Office: 11/12, Sector-'E' Sanwer Road, Industrial Area, Indore (M.P.)

CIN L24233MP1985PLC002709

Email Id: bcplcompliance@gmail.com Phone No. 0731-2426718, 2723016-17 Website: www.biofilgroup.net

Statement of Unaudited Financial Results for the quarter and Half Year ended 30th September 2020

(Amount in Lakhs except EPS)

Statement of Unaudited Financial Results for the quarter and Half Year ended 30th September 2020

Sr No.	Particulars	Quarter Ended			Half Year Ended		Previous Year Ended
		3 Month Ended 30/09/2020	3 Month Ended 30/06/2020	Corresponding 3 months ended in the previous year (30/09/2019)	Year to date figures for current period ended (30/09/2020)	Year to date figures for the previous year ended (30/09/2019)	Year ended March 31 2020
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I	Revenue from Operation	1601.86	230.11	1162.88	1831.97	1322.29	2969.02
II	Other Income	14.59	63.62	3.36	78.21	4.47	17.15
III	Total Revenue (I + II)	1616.45	293.72	1166.24	1910.18	1326.77	2986.17
IV	Expenses						
	(a) Cost of materials consumed	138.95	139.65	97.60	278.60	184.27	405.66
	(b) Purchases of stock-in-trade	75.45	1209.89	2119.94	1285.35	2144.97	2159.45
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	1,252.53	(1122.16)	(1205.14)	130.37	(1,219.09)	(34.23)
	(d) Employee benefits expense	23.25	16.75	21.46	40.00	40.43	86.34
	(e) Finance Cost	2.00	2.45	3.27	4.45	6.86	12.24
	(f) Depreciation and Amortisation Expense	10.88	10.21	9.45	21.09	18.58	40.83
	(g) Other expenses	20.69	15.27	40.53	35.96	67.72	169.47
	Total expenses (IV)	1523.74	272.06	1087.11	1795.80	1243.75	2839.76
V	Profit/(Loss) before exceptional items and tax (III-IV)	92.71	21.66	79.13	114.37	83.02	146.41
VI	Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00
VII	Profit/(Loss) before tax (V - VI)	92.71	21.66	79.13	114.37	83.02	146.41
VIII	Tax expense:						
	(1) Current tax	0.00	0.00	0.00	0.00	0.00	25.69
	(2) Deferred tax Credit/(Charge)	0.00	0.00	0.00	0.00	0.00	0.00
IX	Profit/(Loss) for the period from continuing operation (VII-VIII)	92.71	21.66	79.13	114.37	83.02	120.72
X	Profit/(Loss) from dis-continued operation	0.00	0.00	0.00	0.00	0.00	0.00
XI	Tax expenses of discontinued operation	0.00	0.00	0.00	0.00	0.00	0.00
XII	Profit/(Loss) from dis-continued operation after tax (X-XI)	0.00	0.00	0.00	0.00	0.00	0.00
XIII	Profit/(Loss) for the period (IX+XII)	92.71	21.66	79.13	114.37	83.02	120.72
XIV	Other Comprehensive Income	0.00	0.00	0.00	0.00	0.00	0.00
	A) (I) Items that will not be reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00	0.00
	(II) Income Tax relating to items that will not be reclassified to Profit or Loss				0.00		
	B) (i) Items that will be reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00	0.00
	(II) Income Tax relating to items that will be reclassified to Profit or Loss				0.00		
	c) Other Comprehensive Income (net of tax)	0.00	0.00	0.00	0.00	0.00	2.62
XV	Total Comprehensive Income for the period (XIII + XIV) (Comprising Profit or Loss and other Comprehensive income for the period)	92.71	21.66	79.13	114.37	83.02	123.35
XVI	Paid-Up equity share capital (face value of Rs 10/- each)	1627.38	1627.38	1627.38	1627.38	1627.38	1627.38
XVII	Reserves (Excluding Revaluation Reserve)						-515.27
XVIII	Earnings per equity shares (for continuing operation):						
	(1) Basic (Rs)	0.57	0.13	0.49	0.70	0.51	0.76
	(2) Diluted (Rs)	0.57	0.13	0.49	0.70	0.51	0.76

- 1 The above Un-Audited financial results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on 11th November, 2020. The Unaudited interim financial results for the quarter and half year ended 30th September, 2020 have been subjected to limited review by the statutory auditors, who have expressed an unmodified opinion.
- 2 The financial results of the Company have been prepared in accordance with the recognition and measurement principles laid down in the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and the other accounting principles generally accepted in India.
- 3 The figures of the previous period / year have been re-stated/ re-grouped / re-arranged/ reclassified and / or recasted wherever found necessary.
- 4 The Company has reported segment wise information as per Indian Accounting Standard (Ind AS-108). The Operations of the Company are conducted within India, there is no separate reportable geographical segment and the company reported the following business segments
a. Pharma Product
b. Chemicals Division
- 5 The aforesaid un-audited financial Results will be uploaded on the Company's website www.biofilgroup.net and will also be available on the websites of the Stock exchanges i.e. www.bseindia.com and www.nseindia.com for the benefit of shareholders and investors
- 6 The Earning Per Shares (Basic and Diluted) for the interim period have not been annualized.


Date : 11-11-2020

Place : Indore

For Biofil Chemicals & Pharmaceuticals Limited



RAMESH SHAH
MANAGING DIRECTOR
(DIN: 00028819)



Biofil Chemicals and Pharmaceuticals Limited

Registered Office: 11/12, Sector-'E' Sanwer Road, Industrial Area, Indore (M.P.)

CIN L24233MP1985PLC002709

Email Id:bcplcompliance@gmail.com Phone No. 0731-2426718, 2723016-17

Segmentwise Revenue, Results and Capital Employed for quarter ended 30th September-2020

(Amount in Lakhs)

S.No.	Segment Revenue	Quarter Ended				Year Ended	
		Sep 30 , 2020	June 30 , 2020	Sep 30 , 2019	Sep 30 , 2020	Sep 30 , 2019	31 March 2020
		Reviewed	Reviewed	Reviewed	Reviewed	Audited	Audited
1	Segment Revenue						
	Pharma Unit	1,384.61	24.75	998.46	1,409.36	1,054.05	2,436.17
	Chemicals Division	217.25	205.35	164.42	422.61	268.24	532.85
	Plastic Division		0.00	0.00	0.00	0.00	0.00
	Other	14.59	63.62	2.32	78.21	3.43	19.77
	Gross Turnover	1,616.45	293.72	1,165.20	1,910.18	1,325.73	2,988.79
2	Segment Results						
	Pharma Unit	64.19	-9.92	67.82	54.27	75.88	91.41
	Chemicals Division	30.51	34.01	14.57	64.53	17.53	67.60
	Plastic Division	0.00	0.00	-1.06	0.00	-4.63	-6.81
	Other	0.00	0.00		0.00	0.00	0.00
	Total Segment Profit Before Tax	94.71	24.09	81.33	118.80	88.79	152.20
	Interest Income	0.00	0.00	1.04	0.00	1.04	2.16
	Interest Expenses	2.00	2.44	3.25	4.43	6.81	5.33
	Other Unallocable Income net of Expenditure						
	Profit Before Tax	92.71	21.66	79.13	114.37	83.02	149.03
	Provision for current tax	0.00	0.00		0.00	0.00	24.88
	Item Related Earlier Year	0.00	0.00		0.00	0.00	0.81
	Profit After Tax	92.71	21.66		114.37	83.02	123.35
3	Capital Employed						
	Segment Assets (A)						
	Pharma Division	2,203.60	2,125.11	3,424.07	2,203.60	3,424.07	3,017.03
	Chemicals Division	1,250.61	1,228.95	1,073.39	1,250.61	1,073.39	1,219.47
	Plastic Division	0.00	0.00	51.11	0.00	51.11	0.00
	Other						
	Total (A)	3,454.22	3,354.06	4,548.57	3,454.22	4,548.57	4,236.49
	Segment Liabilities (B)						
	Pharma Division	1,609.82	1,519.12	2,762.38	1,609.82	2,762.38	2,404.93
	Chemicals Division	212.52	254.79	175.91	212.52	175.91	343.24
	Plastic Division	0.00	0.00	143.71	0.00	143.71	0.00
	Other					0.00	
	Total (B)	1,822.34	1,773.91	3,082.00	1,822.34	3,082.00	2,748.18
	Total Capital Employed (Segment Assets- Segment Liabilities)						
	Pharma Division	593.78	605.99	661.69	593.78	661.69	612.09
	Chemicals Division	1,038.09	974.16	897.48	1,038.09	897.48	876.22
	Plastic Division	0.00	0.00	-92.60	0.00	-92.60	0.00
	Other						0.00
	Total Capital Employed (Segment Assets- Segment Liabilities)	1,631.87	1,580.15	1,466.57	1,631.87	1,466.57	1,488.32

DATE : 11/11/2020

PLACE: INDORE

BIOFIL CHEMICALS AND PHARMACEUTICALS LTD.

RAMESH SHAH
MANAGING DIRECTOR
DIN: 00028819



Limited Review Report
(Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements))

To
The Board of Directors
Biofil Chemicals and Pharmaceuticals Limited
Indore

Review report to **Biofil Chemicals and Pharmaceuticals Limited**

We have reviewed the accompanying statement of unaudited financial results of **Biofil Chemicals and Pharmaceuticals Limited** for the period ended 30th September 2020 being submitted by the Company pursuant to Regulation 33 SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including relevant circular issued by the SEBI from time to time. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with Indian Accounting Standard 34, Interim Financial Reporting (Ind As 34) prescribed under section 133 of Companies Act 2013 and generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Based on our review conducted as stated in paragraph 2 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Our conclusion is not modified in respect of this matter.

Place: Indore
Date: 11.11.2020

For Maheshwari & Gupta
Chartered Accountant

CA Sunil Maheshwari
Partner
M No. 403346

UDIN: 20403346 AAAA/L1478